Neuroleptic Malignant Syndrome or a Statin Drug Reaction? A Case Report

被引:8
作者
Cooper, Joyce M. [1 ]
Jones, Alison L. [2 ]
机构
[1] Univ Newcastle, Sch Biomed Sci, Callaghan, NSW 2308, Australia
[2] Univ Newcastle, Dept Clin Pharmacol, Callaghan, NSW 2308, Australia
关键词
neuroleptic malignant syndrome; NMS; statins; myopathy; macrolide; RISK-FACTORS; RHABDOMYOLYSIS;
D O I
10.1097/WNF.0b013e3181acc92d
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A 60-year-old woman with a long psychiatric history presented with delirium and mutism. She was febrile, with marked limb rigidity and elevated creatinine kinase (CK) level. Current medications included pericyazine. Current or recent use of dopamine-blocking agents, such as pericyazine, together with a disturbance in conscious state, autonomic dysfunction, and an elevated CK level may be suggestive of neuroleptic malignant syndrome (NMS). The diagnosis was confirmed as NMS, and she was successfully treated with bromocriptine. Eight years later, she represents with symptoms suggesting recurrence of NMS including elevated CK level and myalgia, however, without limb rigidity. Current medications include quetiapine, lithium, simvastatin, and a recent course of clarithromycin. Macrolide antibiotics such as clarithromycin inhibit the metabolic pathway of statins via the cytochrome CYP450 3A4 hepatic enzyme system and may result in elevated CK level, myopathy, or rhabdomyolysis producing symptoms that may be confused with NMS. Simvastatin was ceased with rapid decrease in CK level and resolution of symptoms. This case highlights the importance of considering other diagnoses in any patient presenting with a disturbance in conscious state, autonomic dysfunction, and an elevated CK level. Particularly in a patient with a history of NMS, a thorough medication history is essential to aid diagnosis and avoid confusion with presenting symptoms and medical history.
引用
收藏
页码:348 / 349
页数:2
相关论文
共 8 条
[1]   Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment [J].
Ananth, J ;
Aduri, K ;
Parameswaran, S ;
Gunatilake, S .
ACTA NEUROPSYCHIATRICA, 2004, 16 (04) :219-228
[2]   Drug-induced myopathies [J].
Argov, Z .
CURRENT OPINION IN NEUROLOGY, 2000, 13 (05) :541-545
[3]   NEUROLEPTIC MALIGNANT SYNDROME [J].
CAROFF, SN ;
MANN, SC .
MEDICAL CLINICS OF NORTH AMERICA, 1993, 77 (01) :185-202
[4]   The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity [J].
Dunkley, EJC ;
Isbister, GK ;
Sibbritt, D ;
Dawson, AH ;
Whyte, IM .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2003, 96 (09) :635-642
[5]   Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: A case report [J].
Kobayashi, Akiko ;
Kawanishi, Chiaki ;
Matsumura, Takehiko ;
Kato, Daiji ;
Furukawa, Ryoko ;
Kishida, Ikuko ;
Hirayasu, Yoshio .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (06) :1170-1172
[6]   Risk factors for rhabdomyolysis with simvastatin and atorvastatin [J].
Ronaldson, Kathlyn J. ;
O'Shea, Justine M. ;
Boyd, Ian W. .
DRUG SAFETY, 2006, 29 (11) :1061-1067
[7]   Statin-associated myopathy [J].
Thompson, PD ;
Clarkson, P ;
Karas, RH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (13) :1681-1690
[8]   Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis [J].
Wappler, F ;
Fiege, M ;
Steinfath, M ;
Agarwal, K ;
Scholz, J ;
Singh, S ;
Matschke, J ;
Esch, JSA .
ANESTHESIOLOGY, 2001, 94 (01) :95-100